Red Light Therapy for Vulvar Lichen Sclerosus: The Evidence So Far

Vulvar lichen sclerosus is a chronic inflammatory skin condition that causes itching, pain, whitening, and scarring of the vulvar and perianal skin, and the standard first-line treatment has been an ultra-potent topical steroid for decades. A handful of small studies have started testing red and near-infrared light, sometimes called photobiomodulation, as an add-on for women whose symptoms don't fully settle on steroids alone. This review walks through what those studies actually found, how strong the evidence really is, and where light therapy fits next to treatments that have far more research behind them.

What Vulvar Lichen Sclerosus Is

Lichen sclerosus (LS) is a long-term inflammatory condition that most often affects the skin of the vulva and the area around the anus. It can occur at any age but is most common in women after menopause and in young girls before puberty. Men can get it too, usually on the foreskin or head of the penis, but the vulvar form is the one most of the light-therapy research has looked at.

The hallmark symptom is intense, persistent itching. Over time the skin can turn white, thin, and crinkly, almost like cigarette paper. Some women develop painful splits or fissures, especially during sex or bowel movements. In more advanced cases, scarring fuses the labia or buries the clitoris, which can permanently change the anatomy and make sex painful or impossible.

Two things make LS more than a comfort problem. First, it tends to be lifelong and relapsing, so treatment is about long-term control rather than a one-time cure. Second, untreated or poorly controlled LS carries a small but real increased risk of vulvar cancer, which is why monitoring matters and why no one should self-treat a suspected case without a diagnosis.

The exact cause isn't fully understood. LS is widely considered an autoimmune-linked condition, meaning the immune system seems to attack the person's own skin, and it's more common in people who have other autoimmune conditions such as thyroid disease. Genetics, hormones, and local skin trauma may all play a role. Because the driver is chronic immune-mediated inflammation, treatments that calm inflammation tend to help, which is part of why steroids work and part of the rationale researchers give for testing light.

Diagnosis is usually clinical, made by a dermatologist or gynecologist who recognizes the pattern, but a skin biopsy is often done to confirm it and, importantly, to rule out cancer or pre-cancerous change. That biopsy step is one reason self-diagnosis is a bad idea: the symptoms of LS can overlap with other vulvar conditions and with early cancer, and only a clinician can sort them out.

Why the standard treatment is a steroid

For decades the cornerstone of treatment has been an ultra-potent topical corticosteroid, usually clobetasol propionate 0.05% ointment. The 2018 British Association of Dermatologists guidelines recommend it as first-line for all women with anogenital LS, typically on a tapering schedule over the first few months and then as needed to keep the disease controlled (BAD guidelines, 2018). A 2026 evidence- and consensus-based guideline from European dermatology groups reaches the same conclusion: potent or ultra-potent topical steroids remain the backbone of care (consensus guideline, 2026).

This matters for the light-therapy conversation. Every credible study of red light or laser in LS has been done as a supplement to steroids or a comparison against them, not as a replacement. Keep that framing in mind for everything below.

How Red Light Therapy Is Supposed to Work

Red light therapy, or photobiomodulation (PBM), uses red (roughly 630-700 nm) and near-infrared (roughly 800-1100 nm) light at doses low enough that they don't heat or burn tissue. The leading theory is that these wavelengths are absorbed by an enzyme in the mitochondria called cytochrome c oxidase. That absorption is thought to nudge cells to make more energy (ATP), shift the balance of reactive oxygen species, and dial down inflammatory signaling.

In skin specifically, researchers propose that PBM may calm the chronic inflammation driving LS, improve local blood flow, and encourage fibroblasts to remodel the thickened, scarred (sclerosed) tissue and lay down healthier collagen. That's the hoped-for mechanism. It's biologically plausible and supported by lab and animal work in wound healing and inflammation more broadly.

But plausibility is not proof. The jump from "light changes cell behavior in a dish" to "light reliably reduces LS symptoms in women" is exactly the gap that clinical trials are supposed to close, and in LS that gap is only partly filled.

There's a second reason to be careful with the mechanism story. The same broad claims, more energy, less inflammation, better collagen, get made for red light in dozens of conditions, from wrinkles to joint pain. A mechanism that explains everything explains nothing in particular. It tells you why a benefit could exist; it can't tell you whether it does, how big it is, or who gets it. For that you need outcomes measured in real patients, ideally against a sham light that looks identical but does nothing. In LS, no published study has used that kind of sham-controlled design yet.

Wavelength and dose matter, and they're hard to pin down

When people say "red light," they're lumping together a wide band of wavelengths and a huge range of doses. The LS studies used everything from 660 nm red to 808 nm and 970 nm near-infrared, and one even mixed in 445 nm blue. Different wavelengths penetrate to different depths and may act on different targets, so results from one device don't automatically transfer to another. On top of that, photobiomodulation is famously dose-dependent: too little does nothing, and too much can actually suppress the response, a pattern researchers call a biphasic dose response. That makes it genuinely difficult to say "use this many minutes at this distance" for LS, because nobody has established the right dose in a proper trial.

Photobiomodulation versus ablative laser

It helps to separate two very different things that both get called "laser" in LS research.

• Photobiomodulation / low-level laser (LLLT): low-power red or near-infrared light, no tissue destruction, no heat damage. This is the same family as at-home red light panels, though the study devices are medical lasers with controlled doses.
• Ablative or fractional laser (CO2, Nd:YAG): high-energy laser that intentionally injures the skin in tiny columns to trigger remodeling. This is a procedure, done in a clinic, and is a separate evidence question.

Most of the buzz about "red light therapy for lichen sclerosus" refers to the first group. This review focuses there, because that's what an at-home red light device could even theoretically relate to.

The Actual Evidence

Here's the honest summary: the evidence for red light / photobiomodulation in vulvar LS is early-stage and weak by clinical-trial standards. It consists of a few small studies, mostly without proper control groups, with short follow-up. The signals are encouraging, but they are not strong enough to call PBM a proven treatment. You can see the full, current literature for yourself in this PubMed search for photobiomodulation in vulvar lichen sclerosus — the short list of results is itself a sign of how thin the evidence base is.

The table below lays out the main human studies that specifically used low-level red or near-infrared light (not ablative laser) in vulvar LS.

A few things stand out. The largest study had 100 women, which is decent, but it had no control group and everyone got the same treatment, so there's no way to know how much of the improvement came from the light versus from continued steroid use, regression to the mean, or simply being watched closely in a study. The blue-diode study showed clean statistics, but with only 12 patients and no comparison arm, those p-values describe a tiny, hand-picked group.

Look closely at the largest study and the limits become clearer. It enrolled 100 women specifically described as having insufficient response to topical treatment, gave all of them ten low-level laser sessions at 808 nm and 500 mW over eight weeks, and measured health-related quality of life before and after (2024, J Obstet Gynaecol). Seven of eight quality-of-life domains improved with statistical significance, and 94 of the 100 women completed the protocol. That's a real, useful signal worth following up. But the authors themselves frame it as a supplement to existing treatment, not a replacement, and without a control arm the study cannot separate the light's effect from the women continuing their topical care, the natural ups and downs of a relapsing disease, or the well-known placebo response that attaches to any new, hands-on therapy for an itchy, distressing condition.

The blue-diode pilot is even smaller. Twelve women received sessions three times a week for two weeks, then follow-up out to sixteen weeks, using a device combining 445 nm, 660 nm, and 970 nm light (2024, Dermatology Reports). Itching fell significantly (p=0.0071), pain fell significantly (p=0.0001), and objective signs like erythema and fissures improved, with benefits holding at the four-month mark and no side effects. Encouraging, again. But twelve is a tiny sample, there was no comparison group, and the mixed wavelengths mean you can't even say which part of the light did the work, if any.

What the grades mean

In evidence terms:

• Single-arm studies (everyone gets the treatment, no comparison) can generate hypotheses but cannot prove cause and effect. People with chronic, fluctuating conditions often improve during any attentive intervention.
• No blinding means patients and clinicians knew they were getting light, which inflates reported symptom relief, especially for subjective outcomes like itch.
• Short follow-up (weeks to a few months) tells us nothing about whether benefits last or whether the cancer risk is affected.

The most measured voice here is the 2023 systematic review, which pooled all laser types and concluded there isn't enough evidence to use laser on its own (systematic review, 2023). That conclusion covers PBM too.

Honest grade

If we borrow the usual scale, the evidence for red light therapy in vulvar LS sits at roughly "emerging / preliminary." There is no large randomized controlled trial. There is no long-term safety or cancer-risk data for PBM in this disease. Anyone telling you red light "treats" or "reverses" lichen sclerosus is going well beyond what the studies support.

It's worth naming what would change that grade. A convincing trial would randomly assign women either to real photobiomodulation plus their usual steroid, or to an identical-looking sham light plus the same steroid, with neither the patient nor the assessor knowing which is which. It would track not just itch and pain scores but objective signs, biopsy changes, and how many women can reduce their steroid use. And it would follow people for a year or more, long enough to say something about durability and, ideally, about the disease's cancer risk. Until a study like that exists, the honest label stays "promising, unproven."

What about ablative laser?

Because the systematic review pooled all laser types, it's fair to ask what the higher-energy lasers showed. Fractional CO2 and Nd:YAG lasers work by a completely different mechanism than red light: they intentionally injure the skin in microscopic columns to trigger a wound-healing and remodeling response. Some studies suggest that, combined with topical steroids, this can help reduce the thinning and atrophy of LS skin. But the same review flagged a high risk of bias in several of these studies and concluded the overall evidence still isn't strong enough to recommend laser of any kind as a standalone treatment (systematic review, 2023). Ablative laser is also a clinical procedure with its own risks and cost, not something remotely related to an at-home red light panel, so it's a separate decision to make with a specialist.

How It Compares to Treatments With Real Evidence

To keep red light in perspective, here's how it stacks up against the options that actually have guideline backing.

The takeaway is that steroids are not just "the old option." They are the only treatment with strong evidence that they reduce scarring and likely lower the cancer risk that makes LS dangerous. Red light therapy has shown none of that. At best, current studies suggest it might help symptoms and quality of life as an extra on top of standard care.

It also helps to understand why steroids hold the top spot. Decades of use, multiple comparative trials, and long-term cohorts have shown that consistent treatment with clobetasol controls symptoms in the large majority of women, helps prevent progressive scarring, and is associated with a lower rate of cancer in those who stay treated and monitored. The 2018 BAD guideline lays out a specific, well-studied tapering schedule for the first three months and a maintenance plan after that (BAD 2018), and the 2026 European consensus guideline reaffirms potent and ultra-potent topical steroids as the foundation of treatment (consensus guideline, 2026). Many women worry about long-term steroid use thinning the skin, but in LS the bigger risk is usually under-treating, and guidelines stress using enough steroid to actually control the disease.

When steroids aren't enough or aren't tolerated, the next options with reasonable evidence are calcineurin inhibitors such as topical tacrolimus, which suppress the local immune response without the steroid-specific concerns. Photobiomodulation sits well below both of these on the evidence ladder. That ordering, strong first, moderate second, investigational third, is exactly the framework a specialist will use, and it's the framework worth carrying into any conversation about trying light.

For context on how light therapy is evaluated in other conditions, see our reviews of red light therapy for psoriasis and eczema and the broader question of what the clinical research actually says about red light therapy.

Safety and Risks

For the low-power red and near-infrared light used in these studies, the safety record so far looks reassuring: across the small published studies, no significant side effects were reported, including in the blue-diode pilot (2024, Dermatology Reports). PBM doesn't burn or cut tissue when dosed correctly, which is part of its appeal.

That said, the safety data are limited by the same problem as the efficacy data: small numbers and short follow-up. A handful of women followed for a few months can't rule out rare or delayed effects.

The bigger safety issue isn't the light itself. It's what you might neglect while using it.

• Vulvar skin is delicate and the area is sensitive. Consumer red light panels are not designed, tested, or cleared for internal or vulvar use. Pointing a high-irradiance panel at genital skin without medical supervision is not the same thing as the controlled medical-laser dosing used in studies.
• The eyes and the goggles question apply to any bright light source. General device safety is covered in red light therapy eye safety and goggles and red light therapy side effects and risks.
• The cancer-monitoring risk is the serious one. LS carries a small but real increased risk of vulvar squamous cell carcinoma. One large cohort found a cumulative VSCC incidence of 6.7% among women with LS, rising to 18.8% in those who also had vulvar intraepithelial neoplasia (Bleeker et al., 2016). Replacing proven steroid treatment and regular vulvar exams with an unproven light gadget could let dangerous changes go unnoticed.

The 2024 BASHH UK guideline on vulval conditions reinforces that women with LS need ongoing clinical follow-up and prompt assessment of any thickened, ulcerated, or non-healing areas (BASHH 2024). Red light therapy does not replace that monitoring.

Who It Might Be For (and Who Should Be Cautious)

Given the weak evidence, red light therapy for LS is best thought of as something you might discuss with a specialist, not something to start on your own.

Might reasonably explore PBM (with a clinician):

• Women already on proper steroid treatment whose itch, pain, or quality of life hasn't fully improved.
• Women being seen in a clinic that offers medical-grade photobiomodulation under supervision, with continued monitoring.
• People who understand they're trying an investigational add-on, not a cure.

Should be cautious or avoid going it alone:

• Anyone using red light instead of prescribed steroids. This is the riskiest choice and isn't supported by any study.
• Anyone with a new lump, sore, ulcer, or area that won't heal. That needs a clinician's eyes and possibly a biopsy, not a light panel.
• People expecting to point an at-home panel at vulvar skin and get the study results. Consumer devices aren't validated for that use or dose.

If you do want to learn how light dose is even measured, our explainer on red light therapy dosing and how to calculate session time shows why the medical-laser parameters in these studies aren't easily reproduced at home.

The Bottom Line

Red light therapy for vulvar lichen sclerosus is a hopeful but unproven idea. Small, mostly uncontrolled studies suggest that low-level red and near-infrared light, added on top of standard treatment, might ease itching and pain and improve quality of life with few side effects. None of that rises to the level of proof, and the strongest review on the subject says laser shouldn't be used as a standalone treatment.

The smart move is to treat LS with what works (an ultra-potent topical steroid, prescribed and monitored), keep up regular vulvar exams because of the cancer risk, and only consider photobiomodulation as a supervised extra if symptoms aren't controlled. Bring the studies to your dermatologist or gynecologist and decide together.

Frequently Asked Questions

Can red light therapy cure lichen sclerosus?

No. There's no cure for lichen sclerosus, and no study shows red light therapy reverses it. The condition is chronic and relapsing, so even the proven treatments aim to control it long-term rather than cure it. The small studies on photobiomodulation report symptom and quality-of-life improvement, not cure, and they were done as a supplement to standard care.

Is red light therapy as good as steroid cream for lichen sclerosus?

No, not by the evidence. Ultra-potent topical steroids are first-line in every major guideline and are the only treatment shown to reduce scarring and likely lower cancer risk. Red light therapy has only small, uncontrolled studies behind it and has never been shown to match steroids. Don't swap one for the other without a specialist's guidance.

Can I treat my lichen sclerosus with an at-home red light panel?

This isn't recommended. Consumer panels aren't designed, tested, or cleared for vulvar use, and the medical lasers used in studies deliver controlled doses to specific points under supervision. Using a home device on delicate genital skin without medical input risks under-treating a condition that needs monitoring for cancer. Talk to your doctor first.

Does red light therapy have side effects for lichen sclerosus?

In the small published studies, low-level red and near-infrared light caused no significant side effects, even in pilot trials of just 12 patients. But these are small, short studies, so rare or long-term effects can't be ruled out. The bigger danger is neglecting proven treatment and cancer surveillance while relying on an unproven device.

How strong is the evidence for red light therapy in lichen sclerosus?

Weak and early-stage. There's no large randomized controlled trial. The main studies are single-arm with no control group, short follow-up, and small numbers, and a 2023 systematic review concluded there isn't enough evidence to use laser as a standalone treatment. The findings are promising enough to justify bigger trials, not strong enough to call PBM a proven therapy.

This article is for general education and is not medical advice. Lichen sclerosus needs diagnosis, treatment, and monitoring by a qualified clinician; talk to your doctor before starting or changing any treatment.